The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for severe RSV disease.
Pfizer said in a statement that ReViral has a portfolio of antiviral drugs, including a follow-up RSV candidate targeting the viral N protein that ... its RSV vaccine RSVpreF for both adults ...
Pfizer's RSVpreF vaccine is in hot pursuit of GSK's shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults. It is also being developed for use in pregnant ...
Approved in August 2023, RSVpreF (Abrysvo) by Pfizer prevents lower respiratory infections caused by RSV and is also used for adults. Nirsevimab (beyfortus), approved in July 2023, provides targeted ...
Several authors disclosed ties to biopharmaceutical companies, including Pfizer, which manufactures the RSVpreF vaccine and funded the study.
Respiratory syncytial virus prefusion F (RSVpreF) vaccine significantly reduced ... This study was funded by Pfizer. Several authors declared receiving grants and personal fees from Pfizer paid ...
“These data suggest use of RSVpreF in older adults, providing an opportunity to reduce severe medically attended RSV disease burden.” Several authors disclosed ties to biopharmaceutical companies, ...
Scroll through TikTok or Instagram and you’ll be inundated with protein-centric recipes. Maximizing protein is a huge trend right now on social media—and not just in the usual suspects ...